Circulating MicroRNAs in blood of patients with prostate cancer

Medina-Villaamil, V.; Martínez-Breijo, S.; Portela-Pereira, P.; Quindós-Varela, María; Santamarina-Caínzos, I.; Antón-Aparicio, Luis; Gómez-Veiga, F.

doi:10.1016/j.acuroe.2014.10.002

Cited by 33 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our data, Medina‐Villaamil et al . detected that circulating miR‐15b in whole blood of patients with localized PCa could act as biomarker to identify PCa patients with high PSA values . To date, the association of miR‐106b expression with PSA values is not known, but this miRNA is known to be frequently overexpressed in PCa patients .…”

Section: Discussionmentioning

confidence: 99%

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that miR-330-3p is up-regulated in the blood of patients with prostate cancer and primary plasma cell leukemia [20,21]. Recent studies have demonstrated that miR-330-3p expression was increased in NSCLC patient tissues, and miR-330-3p was also involved in NSCLC brain metastasis with 53-fold higher expression compared with non-metastasis NSCLC [22,23].…”

Section: Introductionmentioning

confidence: 98%

miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer

Liu¹,

Shi²,

Liu³

et al. 2015

ABBS

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is one of the most common lung cancers, and microRNAs (miRNAs) have been reported to play essential roles in NSCLC. Recent studies have indicated that miR-330-3p expression is up-regulated in NSCLC samples and in tissues of NSCLC brain metastasis. In this study, up-regulation of miR-330-3p expression was confirmed in NSCLC and 20 NSCLC patient samples. Furthermore, miR-330-3p was over-expressed in NSCLC cell lines A549 and H23, and the promotive function of miR-330-3p was investigated in regulating NSCLC cell proliferation and cell cycle distribution. To identify potential target genes of miR-330-3p in NSCLC, the miRNA target prediction databases were used. Luciferase activity assay and real-time RT-PCR analysis confirmed that miR-330-3p is negatively correlated with the expression of early growth response 2 (EGR2). Moreover, it was also found that EGR2 mRNA contains two potential binding sites for miR-330-3p. Knock-down of EGR2 with siRNA was demonstrated to have a similar effect as the over-expression of miR-330-3p in NSCLC cell lines. Taken together, our results show that EGR2 is a target of miR-330-3p.

show abstract

“…The aberrant expression of miRNAs has been linked to tumor initiation, progression and prognosis (8)(9)(10). Of these cancer-associated miRNAs, miR-218 expression has been frequently observed to be decreased in human colon cancer (11,12).…”

Section: Introductionmentioning

confidence: 99%

miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway

Zhang

Shi

Tang

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. Colon cancer is one of the most common and lethal malignancies worldwide. Despite major advances in the treatment of colon cancer, the prognosis remains very poor. Thus, novel and effective therapies for colon cancer are urgently needed. In the present study, the expression status of miR-218 and the role of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway were investigated in colon cancer samples. Firstly, we observed that miR-218 expression was significantly reduced, while PI3K/Akt/mTOR pathway activity was enhanced. The overexpression of miR-218 suppressed the proliferation, migration and invasion of LoVo colon cancer cells, whereas the inhibition of miR-218 promoted these processes. Furthermore, the PI3K/Akt/mTOR signaling pathway was identified as a direct target of miR-218. The upregulation of miR-218 inhibited the activation of the PI3K/Akt/mTOR signaling pathway, as well as the expression of matrix metalloproteinase (MMP)9. The downregulation of miR-218 activated the PI3K/Akt/mTOR signaling pathway and promoted MMP9 expression. Taken together, our results demonstrate that miR-218 suppresses the proliferation, migration and invasion of LoVo colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway and MMP9. Our data indicate that miR-218 is a potential target in the treatment of colon cancer.

show abstract

Circulating MicroRNAs in blood of patients with prostate cancer

Cited by 33 publications

References 27 publications

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer

miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway

Contact Info

Product

Resources

About